1 Market-Beating Artificial Intelligence (AI) ETF That Could Turn $250,000 Into $1 Million
The iShares Expanded Tech Sector ETF (IGM 2.69%) has delivered a compound annual return of 10.3% since it was established in 2001, comfortably beating the S&P 500 (^GSPC 2.51%) which has generated an average annual gain of 7.8% over the same period (as of this writing).
1 Unstoppable Tech ETF That Could Turn $500 Per Month Into $1 Million Within 30 Years
Last week, the Nasdaq-100 technology index officially entered correction territory after declining by more than 14% from its recent record high. The index hosts some of the world's largest technology stocks, particularly those at the forefront of the artificial intelligence (AI) revolution.
Should You Invest in the iShares Expanded Tech Sector ETF (IGM)?
Looking for broad exposure to the Technology - Broad segment of the equity market? You should consider the iShares Expanded Tech Sector ETF (IGM), a passively managed exchange traded fund launched on 03/13/2001.
IGM: Tech Sector's Blistering Growth Outlook Signals Another Year Of Solid Returns
The iShares Expanded Tech Sector ETF is expected to extend its momentum through 2025, driven by robust tech sector growth and favorable macroeconomic conditions. The tech sector's revenue and earnings growth rates are projected to accelerate in 2025. IGM's diversified portfolio, including mega, large, mid, and small caps, offers broad tech exposure, reducing risk and enhancing growth potential.
Power Corporation of Canada: A Dividend Play Resistant To Reinflation
Power Corporation of Canada offers a compelling dividend yield of 5.1% with strong value supported by mark-to-market valuations of its public enterprises below the stock's value. The primary assets contributing to NAV are Great-West Lifeco, a Canadian life insurance company, and IGM Financial, an asset management firm. Both Great-West Lifeco and IGM Financial are valued comparably to their industry peers, and GWL in particular is in an industry that can withstand and even benefits from reinflation.
IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out
IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.
Should You Invest in the iShares Expanded Tech Sector ETF (IGM)?
Looking for broad exposure to the Technology - Broad segment of the equity market? You should consider the iShares Expanded Tech Sector ETF (IGM), a passively managed exchange traded fund launched on 03/13/2001.
The Smartest Artificial Intelligence (AI) ETF to Buy With $500 Right Now
Artificial intelligence (AI) captured the attention of the investing world like few things that have come before. The excitement around the technology thrust companies once known mostly to tech enthusiasts into the mainstream, while firms across Silicon Valley have seen their stocks rocket up to historic highs on the promise of AI.
IGM: I Don't See The Point
iShares Expanded Tech Sector ETF offers broad tech exposure, including traditional tech companies and those in communication services and consumer goods. IGM's sector allocation is heavily weighted towards semiconductors, interactive media, application software, and systems software, posing concentration risk. Compared to XLK and VGT, the Fund has a higher expense ratio and has underperformed due to its broader tech definition.
Is the iShares Expanded Tech Sector ETF a Millionaire Maker?
In theory just about any investment can be a millionaire maker, but the vast majority won't get you there. However, technology stocks have a long history of impressive returns.
Should You Invest in the iShares Expanded Tech Sector ETF (IGM)?
Launched on 03/13/2001, the iShares Expanded Tech Sector ETF (IGM) is a passively managed exchange traded fund designed to provide a broad exposure to the Technology - Broad segment of the equity market.
IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay
IGM Biosciences Inc.'s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company's pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower their ratings.
